Q2 Earnings Estimate for Flora Growth Issued By Roth Capital

Flora Growth Corp. (NASDAQ:FLGC) – Stock analysts at Roth Capital dropped their Q2 2025 EPS estimates for shares of Flora Growth in a note issued to investors on Wednesday, May 14th. Roth Capital analyst W. Kirk now expects that the company will post earnings of ($0.06) per share for the quarter, down from their previous estimate of $0.02. The consensus estimate for Flora Growth’s current full-year earnings is ($0.93) per share. Roth Capital also issued estimates for Flora Growth’s Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.21) EPS.

Flora Growth Stock Performance

Shares of NASDAQ FLGC opened at $0.66 on Friday. The firm has a market cap of $12.83 million, a price-to-earnings ratio of -0.67 and a beta of 2.01. The business’s 50-day simple moving average is $0.59 and its 200-day simple moving average is $0.93. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.64 and a current ratio of 1.02. Flora Growth has a 52 week low of $0.42 and a 52 week high of $2.11.

Flora Growth (NASDAQ:FLGC) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.03). The company had revenue of $11.79 million during the quarter, compared to analyst estimates of $14.79 million. Flora Growth had a negative net margin of 30.99% and a negative return on equity of 268.17%.

Hedge Funds Weigh In On Flora Growth

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC increased its position in shares of Flora Growth by 23.3% during the fourth quarter. Geode Capital Management LLC now owns 130,934 shares of the company’s stock valued at $135,000 after purchasing an additional 24,713 shares during the period. Virtu Financial LLC bought a new position in shares of Flora Growth in the fourth quarter valued at approximately $43,000. Finally, AdvisorShares Investments LLC bought a new position in shares of Flora Growth in the fourth quarter valued at approximately $73,000. Institutional investors own 36.01% of the company’s stock.

About Flora Growth

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products.